Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients

Lung Cancer

Volumn 89, Issue 3, 2015, Pages 337-342

  Shan, Ling ^a   Wang, Ziping ^a   Guo, Lei ^a   Sun, Hongyan ^a   Qiu, Tian ^a   Ling, Yun ^a   Li, Wenbin ^a   Li, Lin ^a   Liu, Xiuyun ^a   Zheng, Bo ^a   Lu, Ning ^a   Ying, Jianming ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Epidermal growth factor receptor; Gene amplification; Lung adenocarcinoma; Mutation; Tumor heterogeneity; Tyrosine kinase inhibitor

Indexed keywords

GEFITINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TISSUE; DRUG EFFICACY; DRUG TOXICITY; DRUG WITHDRAWAL; DUAL COLOR SILVER IN SITU HYBRIDIZATION; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATOR GENE; ONCOGENE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; FOLLOW UP; GENE EXPRESSION; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS; RISK FACTOR; SURVIVAL ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84938746609     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.06.008     Document Type: Article

References (36)

1. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362:2380-2388.
2. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010, 11:121-128.
3. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13:239-246.
4. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
5. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
6. Shigematsu H., Gazdar A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer 2006, 118:257-262.
7. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
8. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
9. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12:735-742.
10. Wu Y.L., Zhou C., Hu C.P., Feng J., Lu S., Huang Y., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014, 15:213-222.
11. Takeda M., Okamoto I., Fujita Y., Arao T., Ito H., Fukuoka M., et al. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. J. Thorac. Oncol. 2010, 5:399-400.
12. Cappuzzo F., Janne P.A., Skokan M., Finocchiaro G., Rossi E., Ligorio C., et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol. 2009, 20:298-304.
13. Tanaka A., Sueoka-Aragane N., Nakamura T., Takeda Y., Mitsuoka M., Yamasaki F., et al. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer 2012, 75:89-94.
14. Sos M.L., Koker M., Weir B.A., Heynck S., Rabinovsky R., Zander T., et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009, 69:3256-3261.
15. Ng K.P., Hillmer A.M., Chuah C.T., Juan W.C., Ko T.K., Teo A.S., et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 2012, 18:521-528.
16. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
17. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
18. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20932-20937.
19. Zhou Q., Zhang X.C., Chen Z.H., Yin X.L., Yang J.J., Xu C.R., et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:3316-3321.
20. Yokoyama T., Kondo M., Goto Y., Fukui T., Yoshioka H., Yokoi K., et al. EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci. 2006, 97:753-759.
21. Liang Z., Zhang J., Zeng X., Gao J., Wu S., Liu T. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer 2010, 10:376.
22. Li A.R., Chitale D., Riely G.J., Pao W., Miller V.A., Zakowski M.F., et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J. Mol. Diagn. 2008, 10:242-248.
23. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005, 23:6829-6837.
24. Soh J., Okumura N., Lockwood W.W., Yamamoto H., Shigematsu H., Zhang W., et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One 2009, 4:e7464.
25. Maruyama R., Nishiwaki Y., Tamura T., Yamamoto N., Tsuboi M., Nakagawa K., et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol. 2008, 26:4244-4252.
26. Miller V.A., Riely G.J., Zakowski M.F., Li A.R., Patel J.D., Heelan R.T., et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J. Clin. Oncol. 2008, 26:1472-1478.
27. LaFramboise T., Weir B.A., Zhao X., Beroukhim R., Li C., Harrington D., et al. Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput. Biol. 2005, 1:e65.
28. Modrek B., Ge L., Pandita A., Lin E., Mohan S., Yue P., et al. Oncogenic activating mutations are associated with local copy gain. Mol. Cancer Res. 2009, 7:1244-1252.
29. Ying J., Guo L., Qiu T., Shan L., Ling Y., Liu X., et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann. Oncol. 2013, 24:2589-2593.
30. Cappuzzo F., Finocchiaro G., Grossi F., Bidoli P., Favaretto A., Marchetti A., et al. Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. J. Thorac. Oncol. 2015, 10:665-672.
31. Dahabreh I.J., Linardou H., Siannis F., Kosmidis P., Bafaloukos D., Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 2010, 16:291-303.
32. Dacic S., Flanagan M., Cieply K., Ramalingam S., Luketich J., Belani C., et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am. J. Clin. Pathol. 2006, 125:860-865.
33. Hirsch F.R., Varella-Garcia M., McCoy J., West H., Xavier A.C., Gumerlock P., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 2005, 23:6838-6845.
34. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
35. Gazdar A.F., Minna J.D. Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prev. Res. (Phil.) 2008, 1:156-160.
36. Zhao Z.R., Wang J.F., Lin Y.B., Wang F., Fu S., Zhang S.L., et al. Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance. Med. Oncol. 2014, 31:810.